OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Side effects of systemic oncological therapies in dermatology
Lisa Zimmer, Julia Vaübel, Elisabeth Livingstone, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2012) Vol. 10, Iss. 7, pp. 475-486
Closed Access | Times Cited: 39
Lisa Zimmer, Julia Vaübel, Elisabeth Livingstone, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2012) Vol. 10, Iss. 7, pp. 475-486
Closed Access | Times Cited: 39
Showing 1-25 of 39 citing articles:
Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors
Juwhan Choi, Sung Yong Lee
Immune Network (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 212
Juwhan Choi, Sung Yong Lee
Immune Network (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 212
Cutaneous adverse effects of the immune checkpoint inhibitors
Lindsey K. Collins, Michael Chapman, Joi B. Carter, et al.
Current Problems in Cancer (2016) Vol. 41, Iss. 2, pp. 125-128
Closed Access | Times Cited: 205
Lindsey K. Collins, Michael Chapman, Joi B. Carter, et al.
Current Problems in Cancer (2016) Vol. 41, Iss. 2, pp. 125-128
Closed Access | Times Cited: 205
Cutaneous adverse effects of targeted therapies
James B. Macdonald, Brooke Macdonald, Loren E. Golitz, et al.
Journal of the American Academy of Dermatology (2015) Vol. 72, Iss. 2, pp. 221-236
Closed Access | Times Cited: 171
James B. Macdonald, Brooke Macdonald, Loren E. Golitz, et al.
Journal of the American Academy of Dermatology (2015) Vol. 72, Iss. 2, pp. 221-236
Closed Access | Times Cited: 171
Ocular Toxicity in BRAF Mutant Cutaneous Melanoma Patients Treated With Vemurafenib
Christina H. Choe, Grant A. McArthur, Ivor Caro, et al.
American Journal of Ophthalmology (2014) Vol. 158, Iss. 4, pp. 831-837.e2
Closed Access | Times Cited: 99
Christina H. Choe, Grant A. McArthur, Ivor Caro, et al.
American Journal of Ophthalmology (2014) Vol. 158, Iss. 4, pp. 831-837.e2
Closed Access | Times Cited: 99
RASopathic Skin Eruptions during Vemurafenib Therapy
Jeannine D. Rinderknecht, Simone M. Goldinger, Sima Rozati, et al.
PLoS ONE (2013) Vol. 8, Iss. 3, pp. e58721-e58721
Open Access | Times Cited: 82
Jeannine D. Rinderknecht, Simone M. Goldinger, Sima Rozati, et al.
PLoS ONE (2013) Vol. 8, Iss. 3, pp. e58721-e58721
Open Access | Times Cited: 82
Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib
Rachael Anforth, Michael Liu, Bao N. Nguyen, et al.
Australasian Journal of Dermatology (2013) Vol. 55, Iss. 4, pp. 250-254
Closed Access | Times Cited: 78
Rachael Anforth, Michael Liu, Bao N. Nguyen, et al.
Australasian Journal of Dermatology (2013) Vol. 55, Iss. 4, pp. 250-254
Closed Access | Times Cited: 78
BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management.
Elisabeth Livingstone, Lisa Zimmer, Julia Vaübel, et al.
PubMed (2014) Vol. 3, Iss. 3, pp. 29-29
Closed Access | Times Cited: 60
Elisabeth Livingstone, Lisa Zimmer, Julia Vaübel, et al.
PubMed (2014) Vol. 3, Iss. 3, pp. 29-29
Closed Access | Times Cited: 60
Nanoscale Integrin Ligand Patterns Determine Melanoma Cell Behavior
Katharina Amschler, Luise Erpenbeck, Sebastian Kruss, et al.
ACS Nano (2014) Vol. 8, Iss. 9, pp. 9113-9125
Closed Access | Times Cited: 50
Katharina Amschler, Luise Erpenbeck, Sebastian Kruss, et al.
ACS Nano (2014) Vol. 8, Iss. 9, pp. 9113-9125
Closed Access | Times Cited: 50
T cell co-stimulatory and co-inhibitory pathways in atopic dermatitis
Chunjiao Zheng, Yuling Shi, Ying Zou
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
Chunjiao Zheng, Yuling Shi, Ying Zou
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma
Sarah Knispel, Lisa Zimmer, Theodora Kanaki, et al.
Expert Opinion on Drug Safety (2017) Vol. 17, Iss. 1, pp. 73-87
Closed Access | Times Cited: 39
Sarah Knispel, Lisa Zimmer, Theodora Kanaki, et al.
Expert Opinion on Drug Safety (2017) Vol. 17, Iss. 1, pp. 73-87
Closed Access | Times Cited: 39
Dabrafenib Therapy for Advanced Melanoma
Van Anh Trinh, Jennifer Davis, Jaime Anderson, et al.
Annals of Pharmacotherapy (2013) Vol. 48, Iss. 4, pp. 519-529
Closed Access | Times Cited: 38
Van Anh Trinh, Jennifer Davis, Jaime Anderson, et al.
Annals of Pharmacotherapy (2013) Vol. 48, Iss. 4, pp. 519-529
Closed Access | Times Cited: 38
Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel
Jade Cury‐Martins, Adriana Pessoa Mendes Eris, Cristina Martinez Zugaib Abdalla, et al.
Anais Brasileiros de Dermatologia (2020) Vol. 95, Iss. 2, pp. 221-237
Open Access | Times Cited: 31
Jade Cury‐Martins, Adriana Pessoa Mendes Eris, Cristina Martinez Zugaib Abdalla, et al.
Anais Brasileiros de Dermatologia (2020) Vol. 95, Iss. 2, pp. 221-237
Open Access | Times Cited: 31
Retinal toxicities of systemic anticancer drugs
Supriya Arora, Thamolwan Surakiatchanukul, Tarun Arora, et al.
Survey of Ophthalmology (2021) Vol. 67, Iss. 1, pp. 97-148
Closed Access | Times Cited: 26
Supriya Arora, Thamolwan Surakiatchanukul, Tarun Arora, et al.
Survey of Ophthalmology (2021) Vol. 67, Iss. 1, pp. 97-148
Closed Access | Times Cited: 26
Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Initiating Treatment with Vemurafenib.
Philip R. Cohen, Agop Y. Bedikian, Kevin B. Kim
PubMed (2013) Vol. 6, Iss. 5, pp. 27-37
Closed Access | Times Cited: 35
Philip R. Cohen, Agop Y. Bedikian, Kevin B. Kim
PubMed (2013) Vol. 6, Iss. 5, pp. 27-37
Closed Access | Times Cited: 35
Exclusive Cutaneous and Subcutaneous Sarcoidal Granulomatous Inflammation due to Immune Checkpoint Inhibitors: Report of Two Cases with Unusual Manifestations and Review of the Literature
Narciss Mobini, Rummit Dhillon, Jason Dickey, et al.
Case Reports in Dermatological Medicine (2019) Vol. 2019, pp. 1-7
Open Access | Times Cited: 22
Narciss Mobini, Rummit Dhillon, Jason Dickey, et al.
Case Reports in Dermatological Medicine (2019) Vol. 2019, pp. 1-7
Open Access | Times Cited: 22
Arzneimittelinduzierter Pruritus
Klaudia Maleki, Elke Weißhaar
Der Hautarzt (2014) Vol. 65, Iss. 5, pp. 436-442
Closed Access | Times Cited: 20
Klaudia Maleki, Elke Weißhaar
Der Hautarzt (2014) Vol. 65, Iss. 5, pp. 436-442
Closed Access | Times Cited: 20
Immunotherapy of melanoma: efficacy and mode of action
Thomas Wieder, Ellen Brenner, Heidi Braumüller, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2015) Vol. 14, Iss. 1, pp. 28-36
Open Access | Times Cited: 19
Thomas Wieder, Ellen Brenner, Heidi Braumüller, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2015) Vol. 14, Iss. 1, pp. 28-36
Open Access | Times Cited: 19
Prospects for MEK inhibitors for treating cancer
Juan Martín-Liberal, Laura Lagares‐Tena, James Larkin
Expert Opinion on Drug Safety (2014) Vol. 13, Iss. 4, pp. 483-495
Closed Access | Times Cited: 17
Juan Martín-Liberal, Laura Lagares‐Tena, James Larkin
Expert Opinion on Drug Safety (2014) Vol. 13, Iss. 4, pp. 483-495
Closed Access | Times Cited: 17
Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy
Pablo Uribe, Rachael Anforth, Richard Kefford, et al.
Melanoma Research (2014) Vol. 24, Iss. 5, pp. 501-503
Closed Access | Times Cited: 13
Pablo Uribe, Rachael Anforth, Richard Kefford, et al.
Melanoma Research (2014) Vol. 24, Iss. 5, pp. 501-503
Closed Access | Times Cited: 13
Spanish Multidisciplinary Melanoma Group (GEM) guidelines for the management of patients with advanced melanoma
Alfonso Berrocal, Enrique Espinosa, Severiano Marín, et al.
European Journal of Dermatology (2015) Vol. 25, Iss. 5, pp. 392-403
Open Access | Times Cited: 12
Alfonso Berrocal, Enrique Espinosa, Severiano Marín, et al.
European Journal of Dermatology (2015) Vol. 25, Iss. 5, pp. 392-403
Open Access | Times Cited: 12
Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha‐2b in metastatic melanoma (phase II DeCOG trial)
A. Degen, Michael Weichenthal, Selma Ugurel, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2013) Vol. 11, Iss. 9, pp. 846-853
Closed Access | Times Cited: 12
A. Degen, Michael Weichenthal, Selma Ugurel, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2013) Vol. 11, Iss. 9, pp. 846-853
Closed Access | Times Cited: 12
Evolution of melanocytic nevi under vemurafenib, followed by combination therapy with dabrafenib and trametinib for metastatic melanoma.
Călin Giurcăneanu, Cornelia Niţipir, Liliana Gabriela Popa, et al.
PubMed (2015) Vol. 23, Iss. 2, pp. 114-21
Closed Access | Times Cited: 9
Călin Giurcăneanu, Cornelia Niţipir, Liliana Gabriela Popa, et al.
PubMed (2015) Vol. 23, Iss. 2, pp. 114-21
Closed Access | Times Cited: 9
Kutane Nebenwirkungen zielgerichteter onkologischer Arzneimittel
Janina Below, Bernhard Homey, Peter Arne Gerber
Der Hautarzt (2016) Vol. 68, Iss. 1, pp. 12-18
Closed Access | Times Cited: 9
Janina Below, Bernhard Homey, Peter Arne Gerber
Der Hautarzt (2016) Vol. 68, Iss. 1, pp. 12-18
Closed Access | Times Cited: 9
The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
Lisa Pappas‐Taffer, Misha Rosenbach, Emily Y. Chu
Current Dermatology Reports (2013) Vol. 2, Iss. 2, pp. 84-100
Open Access | Times Cited: 6
Lisa Pappas‐Taffer, Misha Rosenbach, Emily Y. Chu
Current Dermatology Reports (2013) Vol. 2, Iss. 2, pp. 84-100
Open Access | Times Cited: 6
Correction: RASopathic Skin Eruptions during Vemurafenib Therapy
Jeannine D. Rinderknecht, Simone M. Goldinger, Sima Rozati, et al.
PLoS ONE (2013) Vol. 8, Iss. 10
Open Access | Times Cited: 5
Jeannine D. Rinderknecht, Simone M. Goldinger, Sima Rozati, et al.
PLoS ONE (2013) Vol. 8, Iss. 10
Open Access | Times Cited: 5
